Bibliography
- Pather SI, Rathbone MJ, Senel S. Current status and the future of buccal drug delivery systems. Expert Opin Drug Deliv 2008;5(5):531-42
- Douroumis D. Orally disintegrating dosage forms and taste-masking technologies; 2010. Expert Opin Drug Deliv 2011;8(5):665-75
- Ghosh T, Ghosh A, Prasad D. A Review on new generation orodispersible tablets and its future prospective. Int J Pharm Pharm Sci 2011;3(1):1-7
- Reflection paper: formulations of choice for the paediatric population. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003782.pdf [Cited 31 January 2012]
- Development of paediatric medicines: Points to consider in pharmaceutical development (Revised draft). Available from: http://www.who.int/medicines/services/expertcommittees/pharmprep/Rev2-PaediatricMedicinesDevelopment_QAS08-257Rev1_8102010.pdf [Cited 31 January 2012]
- Pather SI, Khankari R, Siebert J. Quick-dissolving intraoral tablets. In: Ghosh TK, Pfister WR, editors. Drug Delivery to the Oral Cavity: Molecules to Market. Taylor & Francis Group; Boca Raton: 2005. p. 291-310
- Ghosh TK, Chatterjee DJ, Pfister WR, Quick dissolving oral dosage forms: scientific and regulatory considerations from a clinical pharmacology and biopharmaceutics perspective. In: Ghosh TK, Pfister WR, editors. Drug Delivery to the Oral Cavity:Molecules to Market. Taylor & Francis Group; Boca Raton: 2005. p. 337-57
- AdvaTab® Orally Disintegrating Tablets (ODT). Available from: http://www.aptalispharmaceuticaltechnologies.com/tech_advatab.html [Cited 31 January 2012]
- Prosolv® ODT. Available from: http://www.jrspharma.de/Pharma/wEnglisch/produktinfo/productinfo_prosolv_odt.shtml [Cited 31 January 2012]
- Ludiflash® as excipient for paediatric use. Available from: http://www.pharma-ingredients.basf.com/Documents/ENP/Poster/EN/GENPMD316.pdf [Cited 31 January 2012]
- Dixit RP, Puthli SP. Oral strip technology: overview and future potential. J Control Release 2009;139(2):94-107
- In Pharma Technologist website. Available from: http://www.in-pharmatechnologist.com [Cited 8 February 2012]
- Siddiqui MDN, Garg G, Sharma PK. A short review on “A novel approach in oral fast dissolving drug delivery system and their patents”. Adv Biol Res 2011;5(6):291-303
- Hearnden V, Sankar V, Hull K, New developments and opportunities in oral mucosal drug delivery for local and systemic disease. Adv Drug Deliv Rev 2012;64(1):16-28
- Puratchikody A, Prasanth VV, Mathew ST, Buccal drug delivery: past, present and future – a review. Int J Drug Deliv 2011;3:171-84
- Patel VF, Liu F, Brown MB. Advances in oral transmucosal drug delivery. J Control Release 2011;153(2):106-16
- Pathan SA, Iqbal Z, Sahani JK, Buccoadhesive drug delivery systems–extensive review on recent patents. Recent Pat Drug Deliv Formul 2008;2(2):177-88
- Senel S. Potential applications of chitosan in oral mucosal delivery. J Drug Deliv Sci Tech 2010;20(1):23-32
- Morales JO, McConville JT. Manufacture and characterization of mucoadhesive buccal films. Eur J Pharm Biopharm 2011;77(2):187-99
- Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm 2009;71(3):505-18
- Pather SI, Siebert JM, Hontz J, Enhanced buccal delivery of fentanyl using the oravescent drug delivery system. Drug Deliv Technol 2001;1(1):54-7
- Cima Labs, Inc., assignee. Sublingual buccal effervescent. US6974590; 2005
- BEMA® Technology. Available from: http://www.bdsi.com/BEMA_Technology.aspx [Cited 31 January 2012]
- Reuters website article. Available from: http://www.reuters.com/article/2011/04/05/idUS97931+05-Apr-2011+PRN20110405 [Cited 31 January 2012]
- INSYS Therapeutics Announces FDA Approval of SUBSYS® Fentanyl Sublingual Spray. Available from: http://www.insysrx.com/investors/recent-news/?page_id=270&link=http://insysrx.mwnewsroom.com/press-releases/insys-therapeutics-announces-fda-approval-of-subsy-pinksheets-neol-0837674?feed=All [Cited 31 January 2012]
- Abstral Sublingual Tablets. Available from: http://www.medicines.org.uk/EMC/medicine/21371/SPC/Abstral+Sublingual+Tablets [Cited 31 January 2012]
- Generex Oral-lyn. Available from: http://www.generex.com/index.php/id/270 [Cited 31 January 2012]
- Reuters website article2. Available from: http://www.reuters.com/article/2011/05/26/idUS50920+26-May-2011+RNS20110526 [Cited 1 February 2012]
- Reckitt Benckiser Pharmaceuticals, Inc. Receives FDA Approval for Suboxone® (Buprenorphine and Naloxone) Sublingual Film C-III. Available from: http://www.rb.com/FDA-Approval-for-Suboxone-Sublingual-FilmC-III [Cited 31 January 2012]
- FDA News Release. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm281013.htm [Cited 9 February 2012]
- Intermezzo website. Available from: http://www.intermezzorx.com [Cited 9 February 2012]
- Senel S, Hincal AA. Drug permeation enhancement via buccal route: possibilities and limitations. J Control Release 2001;72(1-3):133-44
- Nicolazzo JA, Reed BL, Finnin BC. Buccal penetration enhancers–how do they really work? J Control Release 2005;105(1-2):1-15
- Hassan N, Ahad A, Ali M, Chemical permeation enhancers for transbuccal drug delivery. Expert Opin Drug Deliv 2010;7(1):97-112
- Sohi H, Ahuja A, Ahmad FJ, Critical evaluation of permeation enhancers for oral mucosal drug delivery. Drug Dev Ind Pharm 2010;36(3):254-82
- Moscicka-Studzinska A, Kijenska E, Ciach T. Electroosmotic flow as a result of buccal iontophoresis–buccal mucosa properties. Eur J Pharm Biopharm 2009;72(3):595-9
- Ciach T, Moscicka-Studzinska A. Buccal iontophoresis: an opportunity for drug delivery and metabolite monitoring. Drug Discov Today 2011;16(7-8):361-6
- Jacobsen J. Buccal iontophoretic delivery of atenolol center dot HCl employing a new in vitro three-chamber permeation cell. J Control Release 2001;70(1-2):83-95
- Giannola LI, De Caro V, Giandalia G, Diffusion of naltrexone across reconstituted human oral epithelium and histomorphological features. Eur J Pharm Biopharm 2007;65(2):238-46
- Giannola LI, De Caro V, Giandalia G, Release of naltrexone on buccal mucosa: permeation studies, histological aspects and matrix system design. Eur J Pharm Biopharm 2007;67(2):425-33
- Moscicka AE, Czarnecka K, Ciach T. IntelliDrug implant for medicine delivery in Alzheimer's disease treatment. Macromol Symp 2007;253:134-8
- Oh DH, Chun KH, Jeon SO, Enhanced transbuccal salmon calcitonin (sCT) delivery: Effect of chemical enhancers and electrical assistance on in vitro sCT buccal permeation. Eur J Pharm Biopharm 2011;79(2):357-63
- Hu L, Silva SM, Damaj BB, Transdermal and transbuccal drug delivery systems: enhancement using iontophoretic and chemical approaches. Int J Pharm 2011;421(1):53-62
- Scholz OA, Wolff A, Schumacher A, Drug delivery from the oral cavity: focus on a novel mechatronic delivery device. Drug Discov Today 2008;13(5-6):247-53
- Kohnle J, Wolff A. Intelligent drug delivery from the oral cavity. Med Device Technol 2007;18(2):44-5
- Campisi G, Giannola LI, Florena AM, Bioavailability in vivo of naltrexone following transbuccal administration by an electronically-controlled intraoral device: a trial on pigs. J Control Release 2010;145(3):214-20
- Giannola LI, Paderni C, De Caro V, New prospectives in the delivery of galantamine for elderly patients using the intellidrug intraoral device: in vivo animal studies. Curr Pharm Des 2010;16(6):653-9
- Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005;11(4):S45-53
- Arca HC, Gunbeyaz M, Senel S. Chitosan-based systems for the delivery of vaccine antigens. Expert Rev Vaccines 2009;8(7):937-53
- Senel S. Chitosan-based particulate systems for non-invasive vaccine delivery. Adv Polym Sci 2011;243:111-38
- Reed SG, Bertholet S, Coler RN, New horizons in adjuvants for vaccine development. Trends Immunol 2009;30(1):23-32
- Perrie Y, Mohammed AR, Kirby DJ, Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm 2008;364(2):272-80
- Corradin G, Giudice Gd. Novel adjuvants for vaccines. Curr Med Chem Anti Inflamm AntiAllergy Agents 2005;4(2):185-91
- Kweon MN. Sublingual mucosa: a new vaccination route for systemic and mucosal immunity. Cytokine 2011;54(1):1-5
- Cuburu N, Kweon MN, Song JH, Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 2007;25(51):8598-610
- Song JH, Nguyen HH, Cuburu N, Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci USA 2008;105(5):1644-9
- Hervouet C, Luci C, Cuburu N, Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. Vaccine 2010;28(34):5582-90
- Cuburu N, Kweon MN, Hervouet C, Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic t cells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol 2009;183(12):7851-9
- Ralli-Jain P, Tifrea D, Cheng CM, Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization. Vaccine 2010;28(48):7659-66
- Cho HJ, Kim JY, Lee Y, Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants. Vaccine 2010;28(14):2598-606
- Zhang T, Hashizume T, Kurita-Ochiai T, Sublingual vaccination with outer membrane protein of Porphyromonas gingivalis and Flt3 ligand elicits protective immunity in the oral cavity. Biochem Biophys Res Commun 2009;390(3):937-41
- Amuguni JH, Lee S, Kerstein KO, Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice. Vaccine 2011;29(29-30):4778-84
- Yu M, Vajdy M. A novel retinoic acid, catechin hydrate and mustard oil-based emulsion for enhanced cytokine and antibody responses against multiple strains of HIV-1 following mucosal and systemic vaccinations. Vaccine 2011;29(13):2429-36
- Domm W, Brooks L, Chung HL, Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier. Vaccine 2011;29(40):7080-9
- Appledorn DM, Aldhamen YA, Godbehere S, Sublingual administration of an adenovirus serotype 5 (ad5)-based vaccine confirms toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against hiv antigens despite preexisting Ad5 immunity. Clin Vaccine Immunol 2011;18(1):150-60
- Launay O, Grabar S, Bloch F, Effect of sublingual administration of interferon-alpha on the immune response to influenza vaccination in institutionalized elderly individuals. Vaccine 2008;26(32):4073-9
- Cox LS, Linnemann DL, Nolte H, Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006;117(5):1021-35
- Marogna M, Spadolini I, Massolo A, Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study. J Allergy Clin Immunol 2010;126(5):969-75
- Wise SK, Woody J, Koepp S, Quality of life outcomes with sublingual immunotherapy. Am J Otolaryngol 2009;30(5):305-11
- Bush RK, Swenson C, Fahlberg B, House dust mite sublingual immunotherapy: Results of a US trial. J Allergy Clin Immunol 2011;127(4):974-U225
- Review of essential medicine priorities in ear, nose and throat conditions in children. Available from: http://www.who.int/selection_medicines/committees/subcommittee/2/2nd_NewSection_ENT.pdf [Cited 31 January 2012]
- Passalacqua G, Guerra L, Pasquali M, Efficacy and safety of sublingual immunotherapy. Ann Allergy Asthma Immunol 2004;93(1):3-12
- Kuo CH, Wang WL, Chu YT, Sublingual immunotherapy in children: an updated review. Pediatr Neonatol 2009;50(2):44-9
- Calderon MA, del Rio PR, Demoly P. Sublingual allergen immunotherapy in children: An evidence-based overview. Rev Fr Allergol 2012;52(1):20-25
- Grazax website. Available from: http://www.grazax.com [Cited 31 January 2012]
- Razafindratsita A, Saint-Lu N, Mascarell L, Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 2007;120(2):278-85
- ViVac website. Available from: http://www.vivac.se [Cited 31 January 2012]
- Wainwright M. Photodynamic antimicrobial chemotherapy (PACT). J Antimicrob Chemother 1998;42(1):13-28
- Donnelly RF, McCarron PA, Tunney MM. Antifungal photodynamic therapy. Microbiol Res 2008;163(1):1-12
- Konopka K, Goslinski T. Photodynamic therapy in dentistry. J Dent Res 2007;86(8):694-707
- Mima EGD, Pavarina AC, Dovigo LN, Susceptibility of Candida albicans to photodynamic therapy in a murine model of oral candidosis. Oral Surg Oral Med O 2010;109(3):392-401
- Meisel P, Kocher T. Photodynamic therapy for periodontal diseases: state of the art. J Photochem Photobiol B 2005;79(2):159-70
- Pereira Gonzales F, Maisch T. Photodynamic inactivation for controlling Candida albicans infections. Fungal Biol 2012;116(1):1-10
- Donnelly RF, McCarron PA, Tunney MM, Potential of photodynamic therapy in treatment of fungal infections of the mouth. Design and characterisation of a mucoadhesive patch containing toluidine blue O. J Photochem Photobiol B 2007;86(1):59-69
- Cassidy CM, Tunney MM, McCarron PA, Drug delivery strategies for photodynamic antimicrobial chemotherapy: from benchtop to clinical practice. J Photochem Photobiol B 2009;95(2):71-80
- Negri DRM, Riccomi A, Pinto D, Persistence of mucosal and systemic immune responses following sublingual immunization. Vaccine 2010;28(25):4175-80